FDA Approves Avastin Biosimilar for Six Types of Cancer

The FDA has approved bevacizumab-adcd (Vegzelma) for the treatment of 6 types of cancer. The biosimilar to bevacizumab (Avastin) was approved for recurrent or metastatic nonsquamous non–small cell lung cancer (NSCLC); recurrent glioblastoma; metastatic colorectal cancer; persistent, recurrent, or metastatic cervical cancer; metastatic renal cell carcinoma; and epithelial ovarian, fallopian tube, or primary peritoneal cancer.1